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Background: The South African Expanded Programme on
Immunisation (EPI-SA) currently vaccinates against 10 childhood
vaccine preventable diseases. Six injections are required for pri-
mary vaccination against diphtheria, tetanus, pertussis, polio,
Haemophilus inﬂuenza type b and hepatitis B: three DTaP-IPV//Hib
[Pentaxim®] doses and three monovalent Hep B vaccines to chil-
dren under 12 months of age, with a seventh injection (Pentaxim®
booster) at 18 months. Madhi et al (PIDJ 30:e68 2011) demon-
strated no signiﬁcant difference in the safety and efﬁcacy between
Pentaxim® plus monovalent Hep B and a new fully liquid hexa-
valent vaccine, Hexaxim® (DTaP-IPV-Hib-HepB). Fromahealthcare
provider perspective, combination vaccines could reduce costs,
simplify logistics anddelivery infrastructure, and improvecoverage
with fewer injections. This study aimed to analyse the cost implica-
tions of a switch from the current combination of Pentaxim® plus
monovalent Hep B injections, to a single Hexaxim® injection, from
the public sector perspective.
Methods & Materials: Data were collected to derive direct
costs, i.e. vaccines’ prices (except Hexaxim®, no price yet avail-
able), transportation charges, cold chain storage, vaccine wastage
rate, hazardouswastedisposal andvaccineadministration.All costs
were calculated per dose, and expressed in South African Rand (R)
(USD 1.00=R10.19 per 2013 exchange rate). Indirect costs such as
individual and societal beneﬁts were excluded.
Results: Delivering one dose ofPentaxim® and Hep B costs
R166.30. Reduced volumes result in cost reductions when using
Hexaxim® for: cold storage; hazardous waste disposal; and vac-
cine administration, resulting in an estimated saving of R10.52 to
R29.40 per dose, depending on utilisation of usable cold storage
space.
Conclusion: Implementation of Hexaxim® within EPI-SA is
highly recommended, because it reduces healthcare provider costs
by simplifying logistics and delivery infrastructure. From a com-
munity perspective, such vaccines reduce clinic visits, vaccinators’
errors, number of injections and side effects,which translate to bet-
ter acceptability, convenience and increased compliance. As theuse
of Hexaxim® demonstrates direct and indirect cost savings, poten-
tial public sector introduction should be valued not only in terms
of the price of Pentaxim® and Hep B.
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Background: Pregnant women are at increased susceptibility
to severe inﬂuenza-illness and are recommended by WHO to be a
priority group for inﬂuenza vaccination. The aims of our studywere
to assess the immunogenicity of trivalent IIV (IIV3) in pregnant
women vaccinated during their 2nd/3rd trimester and to calculate
the vaccine efﬁcacy (VE) to PCR-conﬁrmed inﬂuenza illness (PCI).
Methods & Materials: A double-blind, randomized, placebo-
controlled trial was undertaken in Soweto, South Africa in 2011
and 2012. 2116 conﬁrmed HIV-uninfected pregnant women were
randomized to receive either IIV3 or normal saline placebo
intramuscularly. Immune responses to each vaccine-strain, using
hemagglutination-inhibition (HAI) assays were measured pre-
vaccination and one month post-vaccination. HAI titres of ≥1:40
were categorizedas seroprotective andseroconversionwasdeﬁned
as at least a 4-fold increase in titres from pre- to post-vaccination.
Participants were followed until six months post-partum for the
presence of acute respiratory illness or hospitalization for acute
cardio-pulmonary illness. When ILI was conﬁrmed by a study
physicianoropharyngeal andnasopharyngeal swabswerecollected
for inﬂuenza virus testing by real-time PCR.
Results: One month post-vaccination, comparing IIV3 and
placebo-recipients, the proportion of women who seroconverted
were 72.5% vs. 8.1% to A/H1N1pdm09, 64.8% vs. 2.7% to H3N2,
92.3% vs. 2.0% to inﬂuenza-B strain (all comparisons p<0.001).
Post-vaccination, theproportionofwomenwith seroprotectiveHAI
titres were 93.7% vs. 48.0% for A/H1N1pdm09, 78.9% vs. 27.0% for
H3N2 and 97.2% vs. 29.1% for inﬂuenza-B (p<0.001 for all com-
parisons). The vaccine efﬁcacy of IIV3 was 46.1% (95%CI: 6.4% to
69.0%) in protecting against PCI due to homotypic vaccine strains
and 50.4% (95%CI: 14.5 to 71.2) when including the 3 non-vaccine
inﬂuenza B-Yamagata cases that exclusively occurred among the
placebo-recipients. The dominant strain of inﬂuenza virus identi-
ﬁed was H3N2 which composed 22 (57.9%) cases in the placebo
group and 10 (52.6%) in the vaccinees. 174 and 181 IIV-recipients
and placebo-recipients, respectively, had at least one ILI medical
visit. IIV3 was not associated with reduction of ﬁrst episode of ILI
(VE: 4.6%; 95%CI: -15.4% to 21.1%).
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Conclusion: IIV3 vaccination of pregnant women induced good
humoral immune responses likely to be associated with protection
against inﬂuenza virus infection.
http://dx.doi.org/10.1016/j.ijid.2014.03.1308
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Background: Yellow fever virus (YFV) is a positive sense single-
stranded RNA virus that is transmitted by mosquitoes and is
endemic in the tropical regions of Africa and South America. The
World Health Organization has estimated the annual prevalence
of yellow fever to be 200 000 cases, of which more than 90% is
attributed toAfrica.Althoughhighlyefﬁcacious liveattenuatedvac-
cines are available, use of the vaccines in immunocompromised
individuals are contra-indicated and, although rare, vaccine-
associated viscerotropic adverse events have been reported. Hence
development of a safer alternative that can complement the use
of the live vaccines would have application. The aim of this study
was to prepare a DNA-launched Sindbis based replicon encoding
the ED-lll protein of YFV and to characterize the expression of the
ED-lll protein in transfected cells prior to evaluation as a candidate
vaccine in an animal model.
Methods & Materials: The gene encoding wild-type Asibi
strain YFV ED-lll protein was codon optimized and synthesized by
GenScript. The gene was cloned into a DNA based expression sys-
tem carrying the Sindbis genome and designated pSinED-lll. The
pSinED-lll replicon was puriﬁed and utilized for the transfection of
BHK21cells. A similarly constructedDNA launchedSindbis replicon
expressing a reporter gene, green ﬂuorescing protein, was used as
a transfection control. Transfected BHK cellswere assayed 24hours
post-transfection for the expression of the ED-lll protein using an
indirect immunoﬂuorescence assay (IFA). Anti-his6 mouse mono-
clonal antibodies were used to detect the C-terminal histidine tag.
In addition, sera obtained from mice immunized with bacterially
expressed ED-lll, and shown to have an IgG antibody response to
ED-lll, were used to detect ED-lll protein in transfected cells.
Results: The presence of the gene encoding the ED-lll protein in
the construct was conﬁrmed by PCR and sequencing using primers
ﬂanking the cloning site. The detection of the C-terminal histidine
tag and the ED-lll protein in an indirect IFA conﬁrmed the expres-
sion of YFV ED-lll protein in mammalian cells.
Conclusion: IFA conﬁrmed the expression of ED-lll protein from
pSinED-lll. Therefore the immunogenicity of the DNA-launched
Sindbis virus based replicon will be evaluated using mice.
http://dx.doi.org/10.1016/j.ijid.2014.03.1309
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Background: TheWHOhasprequaliﬁed a killed oral cholera vac-
cine (OCV) in 2011, which has been a key measure in facilitating its
use as part of a comprehensive package including water and sani-
tation measures to cholera epidemic affected areas such as Guinea
and Haiti. A recent phase 3 trial enrolling approximately 70,000
adults and children in India demonstrated a 65% cumulative pro-
tective efﬁcacy over 5 years. This is the ﬁrst trial to evaluate the
safety and immunogenicity of a twodoseOCV regimen in anAfrican
population. The vaccine has been evaluated in a large number of
human subjects in India, Vietnam, and Bangladesh, where it has
demonstrated safety, immunogenicity, and clinical protective efﬁ-
cacy. Though we do not expect the vaccine to act differently in the
Ethiopian population, we aim to conﬁrm our understanding of OCV
use in healthy individuals aged 1 year and above in Africa.
Methods & Materials: This was an individually randomized,
controlled, double blinded, placebo controlled trial in 216 subjects,
equally divided among healthy children and adults. Participants
received two doses of vaccine or placebo. Bloodwas drawn tomea-
sure vibriocidal antibody response before the ﬁrst dose (day 0),
before the second dose (day 14), and on day 28.
Results: Preliminary unblinded safety data suggests that the
vaccine is safe, with only 8 adverse events (AE) for both vaccine
and placebo groups. All AEs were mild, self resolved, and were
not clustered following either dose. Full analysis is to be com-
pleted in March, 2014, at which time results comparing vaccine
to placebo recipients for safety and vibriocidal response will be
available. This serves as an important step towards a mass vaccina-
tion demonstration project, aimed to strengthen national cholera
surveillance. These ﬁndings, alongside concurrent efforts in other
high risk regions, can pave the way for the integration of OCV in
both endemic and outbreak settings in Ethiopia, Africa and beyond.
Conclusion: Adverse reactions were observed with similar fre-
quency among vaccine and placebo recipients in both age groups.
Adverse events (AE) were reported within 28 days of any dose in
0% and 1.8% of vaccinees and 5.6% and 1.8% of placebo recipients in
adults and children respectively. All AEs were mild and self resolv-
ing. A robust immune response against Vibrio cholerae O1 was
observed, with an 81% and 77% seroconversion rate in adults and
children. These ﬁndings, alongside concurrent efforts in other high
risk regions, can pave the way for the integration of OCV in both
endemic and outbreak settings in Ethiopia, Africa and beyond. As
the WHO and partners work to create an international stockpile,
safety and immunogenicity data outside of Asia will be support-
